On March 5, 2024, the FTC, the DOJ and the U.S. Department of Health and Human Services announced that they are seeking public comment on private equity investment in the healthcare secto...
The Federal Trade Commission (FTC) announced revised Hart-Scott-Rodino Act (HSR) reporting thresholds and filing fee amounts, up to a $2.335 million fee for the largest deals. Under the ...
The Federal Trade Commission has announced revised thresholds for Section 8 of the Clayton Act. Under the new thresholds, a person may not serve as a director or officer of two competing...
On December 18, 2023, the Department of Justice and the Federal Trade Commission issued the final version of their revised merger guidelines, which include modest changes from the agencie...
More than ever, M&A transactions can be subject to detailed antitrust reviews in multiple jurisdictions. This can complicate deal negotiations, extend closing timelines and raise greater ...
Last week, the FTC alleged that a private equity firm undertook a “multi-year anticompetitive scheme” to dominate Texas anesthesiology practices through: (1) “serial” acquisitions...
Last week, the FTC settled a director interlock lawsuit with EQT/Quantum, which is notable for three key reasons: (1) it confirms the FTC’s focus on enforcing the interlocking directora...
Proposed changes to the HSR Form and Instructions would, if adopted, substantially increase the time and cost of compliance for private equity firms. The proposed rules would require mor...
On July 19, 2023, the DOJ and FTC released a draft overhaul of the merger guidelines (the Draft Guidelines). Some portions of the Draft Guidelines are consistent with agency practice fro...
On July 10, 2023, Judge Jacqueline Scott Corley of the U.S. District Court for the Northern District of California denied the FTC’s motion for a preliminary injunction to block Microsof...
